Search details
1.
Association of D-dimer level with thrombotic events, bleeding, and mortality in Japanese patients with solid tumors: a Cancer-VTE Registry subanalysis.
Int J Clin Oncol
; 29(4): 407-416, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38430303
2.
HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity.
Breast Cancer Res Treat
; 201(2): 317-328, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37378696
3.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat
; 202(3): 485-496, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37676450
4.
Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials.
Support Care Cancer
; 30(10): 8367-8375, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35857127
5.
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.
Qual Life Res
; 31(6): 1829-1836, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-34982354
6.
Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
Acta Med Okayama
; 76(6): 661-671, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36549768
7.
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet Oncol
; 22(1): 74-84, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33387497
8.
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Br J Cancer
; 125(9): 1217-1225, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34480096
9.
Impact of chemotherapy on cognitive functioning in older patients with HER2-positive breast cancer: a sub-study in the RESPECT trial.
Breast Cancer Res Treat
; 188(3): 675-683, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34080094
10.
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
BMC Cancer
; 21(1): 34, 2021 Jan 07.
Article
in English
| MEDLINE | ID: mdl-33413212
11.
Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: A two-stage stochastic dynamic treatment regime approach.
Biometrics
; 77(2): 702-714, 2021 06.
Article
in English
| MEDLINE | ID: mdl-32420624
12.
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Br J Cancer
; 122(12): 1747-1753, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32238920
13.
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial.
Oncologist
; 25(2): e223-e230, 2020 02.
Article
in English
| MEDLINE | ID: mdl-32043762
14.
NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy.
Breast Cancer Res Treat
; 182(2): 325-332, 2020 Jul.
Article
in English
| MEDLINE | ID: mdl-32462261
15.
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Invest New Drugs
; 38(5): 1540-1549, 2020 10.
Article
in English
| MEDLINE | ID: mdl-31950374
16.
Factors affecting enrollment in randomized controlled trials conducted for patients with metastatic breast cancer.
Jpn J Clin Oncol
; 50(8): 873-881, 2020 Aug 04.
Article
in English
| MEDLINE | ID: mdl-32463090
17.
Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry.
Jpn J Clin Oncol
; 50(11): 1246-1253, 2020 Oct 22.
Article
in English
| MEDLINE | ID: mdl-32715307
18.
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Cancer Sci
; 110(9): 2894-2904, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31348579
19.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30745582
20.
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study.
Breast Cancer Res Treat
; 176(3): 631-635, 2019 Aug.
Article
in English
| MEDLINE | ID: mdl-31115845